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Relationship between frequency 
of hypoglycemic episodes and 
changes in carotid atherosclerosis 
in insulin-treated patients with type 
2 diabetes mellitus
Tomoya Mita1, Naoto Katakami2,3, Toshihiko Shiraiwa4, Hidenori Yoshii5, 
Nobuichi Kuribayashi6, Takeshi Osonoi7, Hideaki Kaneto2, Keisuke Kosugi8, 
Yutaka Umayahara9, Masahiko Gosho10, Iichiro Shimomura2 & Hirotaka Watada1
The effect of hypoglycemia on the progression of atherosclerosis in patients with type 2 diabetes 
mellitus (T2DM) remains largely unknown. This is a post hoc analysis of a randomized trial to investigate 
the relationship between hypoglycemic episodes and changes in carotid intima-media thickness (IMT). 
Among 274 study subjects, 104 patients experienced hypoglycemic episodes. Increases in the mean IMT 
and left maximum IMT of the common carotid arteries (CCA) were significantly greater in patients with 
hypoglycemia compared to those without hypoglycemia. Classification of the patients into three groups 
according to the frequency of hypoglycemic episodes showed that high frequency of hypoglycemic 
events was associated with increases in mean IMT-CCA, and left max-IMT-CCA and right max-IMT-CCA. 
In addition, repetitive episodes of hypoglycemia were associated with a reduction in the beneficial 
effects of sitagliptin on carotid IMT. Our data suggest that frequency of hypoglycemic episodes was 
associated with changes in carotid atherosclerosis.
While type 2 diabetes mellitus (T2DM) is a risk factor for cardiovascular disease (CVD), which is one of the major 
causes of morbidity and mortality in these patients1, large randomized clinical trials did not show the benefits 
of strict glycemic control on CVD in patients with established atherosclerosis or longstanding T2DM2–4. On the 
other hand, a recent study reported that the occurrence of hypoglycemia was associated with increased risk of 
CVD and all-cause mortality in insulin-treated patients with type 1 diabetes mellitus (T1DM) and T2DM5.
Hypoglycemia is a common adverse effect of management for diabetes, especially insulin therapy, and a bar-
rier to optimal glycemic control. Hypoglycemia affects blood constituents6,7, inflammatory cytokine levels8,9, and 
coagulation and fibrinolysis factors10,11, all of which might promote the progression of atherosclerosis. Indeed, 
the acute effects of hypoglycemia, such as sympatho-adrenal activation, catecholamine release on inflammation, 
endothelial injury, and pro-atherothrombotic biomarkers12,13, are well known in patients with T1DM. Also, a 
cross sectional study demonstrated that repeated episodes of hypoglycemia were associated with preclinical ath-
erosclerosis evaluated by carotid and femoral echography and measurement of flow-mediated brachial dilatation 
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in patients with T1DM14. However, the long-term effect of hypoglycemia on the progression of atherosclerosis 
remains largely unknown in patients with T2DM.
Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycemic control without increasing the 
risk of hypoglycemia15,16. Recently, we reported that sitagliptin treatment attenuated the increases in carotid 
intima-media thickness (IMT) in insulin-treated patients with T2DM compared with the conventional treat-
ment17. In the same study, we demonstrated that sitagliptin treatment was superior to conventional treatment in 
terms of HbA1c reduction without increasing the incidence of hypoglycemic episodes, consistent with previous 
studies18–20. However, we have not investigated whether hypoglycemic events are associated with a reduction in 
the beneficial effects of sitagliptin on the changes in carotid atherosclerosis.
The aim of the present post hoc-analysis was to investigate the relationship between hypoglycemic events and 
changes in carotid IMT in insulin-treated patients with T2DM.
Results
Participants. In the original study, 104 of 274 patients experienced hypoglycemia (52 of the sitagliptin group 
and 52 of the conventional group) over the 104 week follow-up. There was no significant differences in the mean 
number of hypoglycemic events between the two groups (0.34 ± 0.85 episodes/month/person in the sitagliptin 
group vs 0.36 ± 0.80 in the conventional group). One episode of severe hypoglycemic event occurred in each 
group. Subgroup analysis according to the occurrence of hypoglycemia showed that patients with hypoglycemia 
were older, had lower estimated glomerular filtration rate (eGFR) level, lower C-peptide level and had more fre-
quent use of sulfonylurea and α -glucosidase inhibitors, but were more lean, less likely to be smokers, had lower 
HbA1c, total-cholesterol, triglyceride, hs-CRP (high-sensitivity C-reactive protein) and interleulin-6, and few 
use of glinides (Table 1).
Occurrence of hypoglycemia is associated with the changes in carotid IMT. Of the 274 patients 
in the original study, 243 patients with available carotid IMT data at baseline and 104 weeks were included in this 
post hoc analysis. Among them, 98 patients experienced hypoglycemia (49 of the sitagliptin group and 49 of the 
conventional group). In the analysis of covariance models that included the occurrence of hypoglycemia, age, gen-
der, baseline IMT and the original treatment group (model 1), the changes in mean IMT of the common carotid 
arteries (mean-IMT-CCA) and left maximum IMT of the common carotid artery (max-IMT-CCA), but not right 
max-IMT-CCA, were significantly higher in patients with hypoglycemia than those without (Table 2). Similar 
findings were noted even in the adjusted models, including model 2 (model 1+ body mass index (BMI) + current 
smoking), model 3 (model 2 + HbA1c, total cholesterol, high density lipoprotein-cholesterol, triglyceride and 
systolic blood pressure), model 4 (model 3+ eGFR + angiotensin-converting enzyme inhibitors/angiotensin II 
receptor blocker, statins and anti-platelets), model 5 (model 4 + sulfonylurea + glinides + α -glucosidase inhibi-
tors), and model 6 (model 5 + C-peptide + hsCRP + interleukin 6).
Next, we performed subgroup analysis according to type of treatment. As shown in Table  3, the 
mean-IMT-CCA was significantly increased relative to baseline in patients with hypoglycemia, but not in 
those without hypoglycemia in the conventional group. In addition, the changes in mean-IMT-CCA and left 
max-IMT-CCA tended to be greater in patients with hypoglycemia compared to those without. More impor-
tantly, in patients without hypoglycemia, the changes in mean-IMT-CCA and left max-IMT-CCA, but not right 
max-IMT-CCA, were significantly smaller in the sitagliptin treatment group than those in the conventional treat-
ment group, while these findings were not observed in patients with hypoglycemia (Table 3). These data showed 
that hypoglycemia was associated with a reduction in the beneficial effects of sitagliptin.
Frequency of hypoglycemia is associated with changes in carotid IMT. Next, to investigate 
the relationship between the frequency of hypoglycemia and changes in carotid IMT, we divided patients 
with the occurrence of hypoglycemia into three groups; patients without hypoglycemia, patients with less 
than 1 times/month hypoglycemia, and patients with more than 1 times/month hypoglycemia. Trend asso-
ciations across three groups and changes in IMT were evaluated by univariate and multivariate linear regres-
sion analyses (Table 4). The frequency of hypoglycemia was associated with changes in mean-IMT-CCA and 
left max-IMT-CCA, but not right max-IMT-CCA in unadjusted model (model 1). Almost similar findings 
were noted even in the adjusted models, including model 2 (model 1 + baseline IMT), model 3 (model 2+ 
age + gender + the original treatment group), model 4 (model 3+ BMI + current smoking), model 5 (model 
4 + HbA1c, total cholesterol, high density lipoprotein-cholesterol, triglyceride and systolic blood pressure), 
model 6 (model 5 + eGFR + angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, stat-
ins and anti-platelets), model 7 (model 6 + sulfonylurea + glinides + α -glucosidase inhibitors), and model 8 
(model 7 + C-peptide + hsCRP + interleukin 6). In addition, analysis of data of the entire population showed that 
increased frequency of hypoglycemia was associated with changes in mean-IMT-CCA (P for difference among 
the three groups = 0.002), right max-IMT-CCA (P = 0.032), and left max-IMT-CCA (P = 0.02) (Fig. 1).
Changes in other parameters. The change in HbA1c (value at end of study - value at baseline) was compa-
rable between the hypoglycemia group (− 0.2 ± 0.9%) and no-hypoglycemia group (− 0.4 ± 1.1%) (Supplementary 
Table 1). Similarly, there were no differences in changes in other risk factors for atherosclerosis such as hyperten-
sion and lipid parameters during the observation period (Supplementary Table 1).
Discussion
Hypoglycemia is a common adverse effect of insulin treatment for T2DM21. Previous studies demonstrated that 
the frequency of hypoglycemic episodes remains unacceptably high even when DPP-4 inhibitors are added to 
insulin therapy, although they did not increase the incidence of hypoglycemic episodes18–20. The same appears 
to be true in the present study. Indeed, the high frequency of hypoglycemic events is associated with increases 
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in carotid atherosclerosis. Previous studies identified several factors, such as BP, BMI22 and lipid parameters23, 
but not hypoglycemic events, to be associated with the changes in carotid artery atherosclerosis in patients with 
T2DM. Thus, this was the first study to demonstrate that frequent episodes of hypoglycemia are associated with 
changes in carotid artery atherosclerosis in insulin-treated patients with T2DM.
While most clinical data showing associations between hypoglycemia and adverse CV risk/mortality risk have 
derived from “serious hypoglycemic” episodes24–26, the effect of mild hypoglycemia on adverse CV outcomes 
Parameters Hypoglycemia group (n = 104) No-Hypoglycemia group (n = 170) P value
Mean number of hypoglycemic events (n/month/person) 0.93 ± 1.13 0.00 ± 0.00 < 0.001
Age (years) 65.6 ± 9.4 62.6 ± 10.0 0.014
Gender (males) (%) 59 (57) 106 (62) 0.38
Body Mass Index 24.3 ± 3.7 25.5 ± 4.2 0.021
Systolic blood pressure (mmHg) 130 ± 15 132 ± 15 0.24
Diastolic blood pressure (mmHg) 74 ± 10 75 ± 12 0.32
Current smoking 30 (22) 29 (21) 0.22
Hypertension 60 (58) 101 (59) 0.80
Dyslipidemia 61 (59) 114 (67) 0.19
Duration of diabetes (years) 18.6 ± 8.5 16.5 ± 8.5 0.053
HbA1c (%) 7.8 ± 0.8 8.2 ± 1.1 0.011
HbA1c (mmol/mol) 62.2 ± 8.9 65.8 ± 12.3 0.011
C-peptide (ng/ml) 0.32 ± 0.24 0.44 ± 0.25 < 0.001
Total cholesterol (mmol/l) 4.79 ± 0.76 5.10 ± 0.94 0.005
LDL cholesterol (mmol/l) 2.67 ± 0.66 2.90 ± 0.78 0.014
HDL cholesterol (mmol/l) 1.47 ± 0.42 1.39 ± 0.35 0.09
Triglyceride (mmol/l) 1.04 (0.69, 1.69) 1.21 (0.97, 1.74) 0.008
eGFR (mL/min/1.73 m2) 73.9 ± 17.6 81.7 ± 24.9 0.006
UAE (mg/g creatinine ) 18.7 (7.1, 59.8) 19.7 (9.3, 88.2) 0.52
hsCRP (ng/dl) 380 (209, 911) 523 (264, 1340) 0.042
IL-6 (ng/dl) 1.5 (1.1, 2.2) 2.1 (1.4, 3.4) < 0.001
ICAM-1 (ng/ml) 229 (193, 278) 228 (181, 265) 0.59
VCAM-1 (ng/ml) 736 (634, 920) 774 (662, 977) 0.22
Mean IMT-CCA (mm) 0.85 ± 0.20 0.83 ± 0.19 0.35
Right maximum IMT-CCA (mm) 1.10 ± 0.36 1.02 ± 0.34 0.073
Left maximum IMT-CCA (mm) 1.11 ± 0.35 1.10 ± 0.38 0.82
Use of oral glucose-lowering agents
Metformin 41 (39) 56 (33) 0.3
Sulfonylurea 21 (20) 11 (6) < 0.001
Glinides 1(1) 20 (12) < 0.001
Thiazolidinediones 9 (9) 15 (9) 1.00
α -glucosidase inhibitors 44 (42) 39 (23) 0.001
Use of anti-hypertensive agents
Angiotensin-converting enzyme inhibitors 4 (4) 8 (5) 1.00
Angiotensin II receptor blockers 50 (48) 72 (42) 0.38
Calcium channel blocker 30 (29) 54 (32) 0.69
Diuretic drugs 10 (10) 15 (9) 0.83
α -adrenergic receptor antagonist 2 (2) 2 (1) 0.64
β -adrenergic receptor antagonist 2 (1) 1 (1) 0.56
Use of lipid-lowering agents
Statins 46 (44) 83 (49) 0.53
Ezetimibe 8 (8) 6 (4) 0.16
Fibrates 3 (3) 4 (2) 1.00
Use of anti-thrombotic agents
Antiplatelet agents 23 (22) 36 (21) 0.88
Table 1.  Clinical characteristics of patients of the two groups. Data are number (%) of patients or mean ± SD 
values or median (range) values. Differences in parameters between groups were analyzed by the Student’s 
t-test or Wilcoxon’s rank sum test for continuous variables and Fisher’s exact test for categorical variables. CCA, 
common carotid artery; estimated glomerular filtration rate; ICAM-1, intercellular adhesion molecule 1; IMT, 
intima-media thickness; ICAM-1, intercellular adhesion molecule 1; VCAM-1, vascular cell adhesion molecule 
1; IL-6, interleukin 6; hs-CRP, high-sensitivity C-reactive protein; UAE, urinary albumin excretion.
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remains still unknown. On the other hand, virtually, this study showed the relation between frequency of mild 
hypoglycemia and changes in IMT because most of the hypoglycemic episodes were mild. In this regard, further 
prospective large sample size studies are required to address whether mild hypoglycemia is also associated with 
adverse CV risk/mortality risk
In this study, patients with hypoglycemia were older, suffered more severe renal dysfunction, had less endog-
enous insulin and more frequent use of sulfonylurea. Thus, it is possible that hypoglycemia is only a maker of 
patients with advanced stages of T2DM and/or those prone to CVD. However, the occurrence of hypoglycemia 
was still associated with the changes in carotid IMT even after adjustment for these confounders. Furthermore, 
the control of atherosclerosis risk factors was not consistently worse in patients with the occurrence of hypogly-
cemia because they were less obese, were less likely to be smokers, achieved better glycemic and lipid controls and 
had lower serum levels of inflammatory cytokines, reflecting patients who were at lower risk for CVD. Indeed, 
almost similar findings were observed in analysis of covariance models after adjustment for those confounding 
factors. These data support that hypoglycemia by itself seem to be a contributing factor for atherosclerosis.
The mechanism of the deleterious effect of hypoglycemia on carotid vascular wall may be multidimensional 
and possibly involves changes in blood constituents6,7, inflammation8,9, and coagulation and fibrinolysis10,11, 
through counter-regulatory defense responses to hypoglycemia. While these responses and changes are transient 
and play a crucial role in protecting vital organs, previous studies demonstrated that acute insulin-induced hypo-
glycemia can provoke inflammatory response, platelet aggregation and endothelial dysfunction in patients with 
T1DM12,27. Thus, the progression of atherosclerosis may be accelerated if hypoglycemic episodes occur frequently. 
However, repeated episodes of relatively mild hypoglycemia have been shown to reduce the counter-regulatory 
defense responses to hypoglycemia in intensive treatment of T2DM28. Nevertheless, at least in Goto-Kakizaki 
rats, diabetic model rats, these responses never disappear and enhance monocyte adhesion to endothelial cells in 
the aorta, leading to increased intimal thickening29. In agreement with this finding, our data demonstrated that 
changes in carotid atherosclerosis increased with increased number of hypoglycemic events.
What is the precise mechanism through which repeated episodes of hypoglycemia promote the progression of 
atherosclerosis? In the present study, we did not find any association between serum biomarkers of inflammation 
or endothelial injury and frequency of hypoglycemia or carotid IMT changes (data not shown). It is possible 
that this negative relationship may be due to several limiting features of such biomarkers. Indeed, the amount 
of such biomarkers is known to be affected by both transient and chronic non-atherosclerotic diseases and drug 
treatment within a relatively short time30. In the future, it would be interesting to determine whether repeated 
episodes of hypoglycemia could affect plaque characteristics of the carotid arteries evaluated by sophisticated 
studies such as Computed Tomography and Magnetic Resonance Imaging. These studies might shed light on 
pro-inflammatory effects of repetitive hypoglycemia on the vasculature. Another possibility is that hypoglycemia 
directly induced hypercatecholaminemia by acting on the vascular wall29,31. However, it is difficult to evaluate 
serum catecholamine levels during hypoglycemia in clinical setting. Further studies are required to clarify the 
mechanism of the influence of hypoglycemia on the vasculature.
It is reported that glucagon-like peptide-1 (GLP-1) attenuates hypoglycemia-induced oxidative stress, inflam-
mation and endothelial dysfunction in patients with T1DM27. Therefore, there is a great interest in determining 
whether DPP-4 inhibitors play an important role in protecting against hypoglycemia-induced vascular damages. 
In this regard, our data suggest that repetitive episodes of hypoglycemia are associated with a reduction in the 
beneficial effects of sitagliptin on the changes in carotid atherosclerosis. The different results may be due to the 
different subjects (T1DM vs. T2DM) or different levels of GLP-1 (DPP-4 inhibitor vs. GLP-1). In any case, when 
DPP-4 inhibitors are used as add-on therapy to insulin therapy, one should take precaution against potential 
hypoglycemia by, for example, reducing the dose of insulin.
Study limitations. The present study has certain limitations. First, this was a post hoc and exploratory anal-
ysis of a randomized unblinded trial and the sample size was relatively small. The analysis is limited by the study 
design and this make the significance of the findings less clear. Thus, the results should be interpreted with cau-
tion. Second, we evaluated self-reported hypoglycemic events through self-monitoring of blood glucose (SMBG) 
levels and hypoglycemic symptoms. Thus, there may be a risk of underestimation of the incidence of hypoglyce-
mic episodes. In an effort to overcome possible recall bias, we confirmed the occurrence of hypoglycemia at each 
visit of each patient. Third, we did not evaluate hypoglycemia awareness status. Since some episodes of non-severe 
hypoglycemia could be asymptomatic, they were unreported by patients. Thus, we could not rule out possible 
underestimation of the deleterious effects of hypoglycemia on carotid atherosclerosis. Fourth, there were some 
discrepancies in the results of carotid IMT although the results showed a similar pattern. These differences may 
be due to the underpowered sample and side difference in IMT-CCA32.
Conclusions
Our data suggest that frequent episodes of hypoglycemia were associated with changes in carotid atherosclerosis 
in insulin-treated patients with T2DM. Physicians need to take care in avoiding the occurrence of hypoglycemic 
episodes in the clinical setting in order to minimize the process of atherosclerogenesis.
Methods
Study population. We performed a post hoc analysis from the Sitagliptin Preventive study of Intima-media 
thickness Evaluation (SPIKE). The study design, inclusion and exclusion criteria, study schedule and measure-
ments were described in detail previously17,33. Briefly, insulin-treated Japanese T2DM patients free of past history 
of apparent CVD who periodically attended the Outpatient Diabetes Clinics at 12 centers across Japan were 
asked to participate in this study. A total of 282 participants were randomly allocated to either the sitagliptin 
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group (n = 142) or the conventional treatment group (using drugs other than the DPP-4 inhibitor) (n = 140). 
Finally, 137 in the sitagliptin group and 137 in the conventional treatment group were included in the full analysis 
set. Each participant underwent ultrasonography of the carotid arteries including mean-IMT-CCA and in the 
right and left max-IMT-CCA performed by expert sonographers at the start of the study, and the procedure was 
repeated after 52 and 104 weeks.
All patients who agreed to participate were entered into the study. The protocol was approved by the 
Institutional Review Board of each participating institution (Juntendo University Graduate School of Medicine, 
Osaka University Graduate School of Medicine, Juntendo Tokyo Koto Geriatric Medical Center, Naka Memorial 
Clinic, Osaka Police Hospital, Osaka General Medical Center, Kansai Rosai Hospital, Sasebo Chuo Hospital, 
Jiyugaoka Medical Clinic, Ikeda Municipal Hospital) in compliance with the Declaration of Helsinki and current 
legal regulations in Japan. Written informed consent was obtained from all the participants after full explanation 
of the study. This study has been registered on the University Hospital Medical Information Network Clinical 
Trials Registry, which is a non-profit organization in Japan and meets the requirements of the International 
Committee of Medical Journal Editors (UMIN000007396).
Definition of hypoglycemia. All adverse events including hypoglycemia were recorded at each visit during 
study, as described previously17. During the study, participants were asked to submit their records of SMBG and 
whether they had a sign and symptoms of hypoglycemia. Hypoglycemia was defined based on confirmation by 
measurement of plasma glucose of ≤ 3.9 mmol/L and/or self-reported probable hypoglycemic symptom. Severe 
hypoglycemia was defined as events requiring aid of another person to administer treatment.
Measurement of carotid IMT. Ultrasonographic scans of the carotid artery were performed by expert 
sonographers who were specifically trained to perform the prescribed study examination, as reported previ-
ously17,33. To avoid inter-sonographer variability, each participant was examined by the same sonographer with 
the same equipment throughout all the visits. To avoid inter-reader variability, all scans were electronically stored 
and emailed to the central office (IMT Evaluation Committee, Osaka, Japan) to be read by a single experienced 
reader blinded to the clinical features of the patients, in a random order, using automated digital edge-detection 
software (Intimascope; MediaCross, Tokyo, Japan)17,33. The software system averages 200 points of IMT values 
in the segment 2 cm proximal to the dilation of the carotid bulb (mean-IMT-CCA). In addition, the greatest 
Hypoglycemia group No-Hypoglycemia group Adjusted mean difference between groups P value
Mean IMT-CCA (mean change from baseline; SE)
Model 1 0.027 (0.015) − 0.023 (0.012) − 0.050 (− 0.088, − 0.013) 0.009
Model 2 0.027 (0.015) − 0.023 (0.012) − 0.050 (− 0.088, − 0.012) 0.010
Model 3 0.031 (0.015) − 0.023 (0.012) − 0.054 (− 0.093, − 0.015) 0.007
Model 4 0.030 (0.015) − 0.023 (0.012) − 0.052 (− 0.092, − 0.013) 0.010
Model 5 0.026 (0.016) − 0.020 (0.012) − 0.047 (− 0.088, − 0.005) 0.027
Model 6 0.027 (0.016) − 0.021 (0.013) − 0.048 (− 0.090, − 0.006) 0.027
Right maximum IMT-CCA (mean change from baseline; SE)
Model 1 0.041 (0.035) − 0.007 (0.029) − 0.048 (− 0.139, 0.043) 0.30
Model 2 0.039 (0.036) − 0.006 (0.029) − 0.046 (− 0.138, 0.046) 0.33
Model 3 0.042 (0.036) − 0.007 (0.029) − 0.049 (− 0.143, 0.046) 0.31
Model 4 0.042 (0.036) − 0.007 (0.029) − 0.049 (− 0.143, 0.046) 0.31
Model 5 0.045 (0.037) − 0.009 (0.030) − 0.054 (− 0.153, 0.045) 0.28
Model 6 0.049 (0.037) − 0.012 (0.030) − 0.061 (− 0.160, 0.038) 0.22
Left maximum IMT-CCA (mean change from baseline; SE)
Model 1 0.027 (0.029) − 0.053 (0.024) − 0.081 (− 0.155, − 0.007) 0.032
Model 2 0.032 (0.029) − 0.057 (0.024) − 0.089 (− 0.164, − 0.014) 0.020
Model 3 0.036 (0.029) − 0.057 (0.024) − 0.093 (− 0.169, − 0.016) 0.017
Model 4 0.033 (0.029) − 0.055 (0.024) − 0.088 (− 0.164, − 0.012) 0.024
Model 5 0.029 (0.030) − 0.053 (0.024) − 0.082 (− 0.161, − 0.002) 0.045
Model 6 0.024 (0.031) − 0.049 (0.024) − 0.074 (− 0.155, 0.008) 0.075
Table 2.  Changes in intima-media thickness from baseline by analysis of covariance models. Differences in 
delta change in IMT from baseline between two groups were analyzed with analysis of covariance models that 
included the presence of hypoglycemia, age, gender, baseline IMT and the original treatment group (Model 1),  
model 1 plus body mass index and current smoking (Model 2), model 2 plus HbA1c, total cholesterol, high 
density lipoprotein-cholesterol, triglyceride and systolic blood pressure (Model 3), model 3 plus estimated 
glomerular filtration rate, use of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, 
use of statins and use of anti-platelets (Model 4), model 4 plus the use of sulfonylurea, the use of glinides and 
the use of α -glucosidase inhibitors (Model 5), model 5 plus C-peptide, high-sensitivity C-reactive protein and 
interleukin (Model 6). CCA, common carotid artery; IMT, intima-media thickness.
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thicknesses of IMT, including plaque lesions in the common carotid arteries (max-IMT-CCA) were also meas-
ured separately. The reproducibility of IMT measurement was very high as described previously17.
Statistical analysis. Data were reported as mean ± SD. Statistical analysis was performed using analysis of 
covariance models that included several variables in addition to occurrence of hypoglycemia, such as age, gender 
and baseline IMT (see Table 2 for details). Baseline and follow-up group comparisons were assessed with the 
Parameters Hypoglycemia Sitagliptin group Conventional group P value
Change in mean IMT-CCA
No − 0.057 ± 0.140 (n = 72)§ 0.012 ± 0.138 (n = 73) 0.003
Yes 0.012 ± 0.201 (n = 49) 0.042 ± 0.135 (n = 49)* 0.38
Change in right max IMT-CCA
No − 0.039 ± 0.243 (n = 72) 0.041 ± 0.412 (n = 73) 0.16
Yes 0.062 ± 0.470 (n = 48) − 0.007 ± 0.295 (n = 49) 0.39
Change in left max IMT-CCA
No − 0.105 ± 0.298 (n = 72)# − 0.003 ± 0.304 (n = 73) 0.042
Yes − 0.005 ± 0.393 (n = 49) 0.060 ± 0.266 (n = 49) 0.34
Table 3.  Changes in IMT from baseline at 104 weeks in patients treated with or without sitagliptin in 
subgroup analysis based on the occurrence of hypoglycemia. Data are mean ± SD. Differences in parameters 
from baseline to 104 weeks within group were analyzed by one-sample t-test. Differences in parameters from 
baseline to 104 weeks between groups were analyzed by the Student’s t-test. *P < 0.05, #P < 0.01, §P < 0.001.
Variable
Regression coefficient (95% 
Confidence Interval) P value
Change in mean IMT-CCA
Model 1 0.047 (0.019–0.075) < 0.001
Model 2 0.048 (0.021–0.075) < 0.001
Model 3 0.043 (0.016–0.070) 0.002
Model 4 0.050 (0.012–0.088) 0.01
Model 5 0.054 (0.015–0.093) 0.007
Model 6 0.052 (0.013–0.092) 0.01
Model 7 0.047 (0.005–0.088) 0.027
Model 8 0.044 (0.014–0.074) 0.005
Change in right max IMT-CCA
Model 1 0.052 (− 0.014–0.118) 0.12
Model 2 0.064 (0.001–0.128) 0.045
Model 3 0.058 (− 0.005–0.122) 0.073
Model 4 0.046 (− 0.046–0.138) 0.33
Model 5 0.049 (− 0.046–0.143) 0.31
Model 6 0.049 (− 0.046–0.143) 0.31
Model 7 0.054 (− 0.045–0.153) 0.28
Model 8 0.069 (− 0.002–0.139) 0.058
Change in left max IMT-CCA
Model 1 0.077 (0.019–0.134) 0.009
Model 2 0.078 (0.026–0.130) 0.004
Model 3 0.070 (0.018–0.123) 0.009
Model 4 0.089 (0.014–0.164) 0.02
Model 5 0.093 (0.016–0.169) 0.017
Model 6 0.088 (0.012–0.164) 0.024
Model 7 0.082 (0.002–0.161) 0.045
Model 8 0.069 (0.011–0.127) 0.021
Table 4.  Trend associations across groups divided by frequency of hypoglycemia and changes in IMT. 
Model 1: Trend estimation for linear trends across quintiles is based on linear regression analysis for continuous 
variables unadjusted (Model 1), adjusted for model 1 plus baseline IMT (Model 2), model 2 plus age, gender, 
baseline IMT and the original treatment group (Model 3), model 2 plus body mass index and current smoking 
(Model 4), model 4 plus HbA1c, total cholesterol, high density lipoprotein-cholesterol, triglyceride and systolic 
blood pressure (Model 5), model 4 plus estimated glomerular filtration rate, use of angiotensin-converting 
enzyme inhibitors/angiotensin II receptor blockers, use of statins and use of anti-platelets (Model 6), model 6 
plus the use of sulfonylurea, the use of glinides and the use of α -glucosidase inhibitors (Model 7), model 7 plus 
C-peptide, high-sensitivity C-reactive protein and interleukin (Model 8). CCA, common carotid artery; IMT, 
intima-media thickness.
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Student’s t-test or Wilcoxon’s rank sum test for continuous variables and Fisher’s exact test for categorical varia-
bles. Changes from baseline to treatment visits were assessed with one-sample t-test and Wilcoxon’s signed rank 
test within the group. We categorized patients into the following three groups according to the number of hypo-
glycemic episodes during follow-up: 1) those with no episodes, 2) those with less than one episode per month, 
and 3) those with one or more episodes. Comparisons among the three groups were performed by one-way anal-
ysis of variance. Trend associations across the three groups and changes in IMT were evaluated by univariate and 
multivariate linear regression analyses. All statistical tests were two-sided with 5% significance level. All analyses 
were performed using the SAS software version 9.4 (SAS Institute, Cary, NC).
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